Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

US11116834B2 · kind B2 · utility

Assignee

• City of Hope · US

Inventors

• John C. Williams · Duarte, US
• Christine E. Brown · Duarte, US
• Don J. Diamond · Glendora, US

Key dates

• Filing date: Oct 19, 2017
• Grant date: Sep 14, 2021
• Expiry date: Dec 29, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2710/16134
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are, inter alia, methods and compositions including T cells expressing (i) a recombinant CAR protein which includes a peptide binding site and is capable of specifically binding cancer-specific antigens and (ii) a T cell receptor specific for a viral antigen (e.g., a CMV pp65 protein). The engineered T cells provided herein may be used in combination with a viral vaccine (e.g. cytomegalovirus (CMV) Triplex Vaccine) to treat a variety of cancers. The methods described herein also permit in viva expansion of CMV-specific CAR T cells, instead of or in addition to ex vivo expansion, avoiding excessive T cell exhaustion that results in some cases from ex vivo manufacturing.